Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 2/20 | 0.45 |
| ▸ | TNKS | O95271 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 5/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | MMP12 | P39900 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
| ▸ | TOP2A | P11388 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25612247 | 0.94 | MMP12 (0.45) | AHRTNKSMEN1KMT2AMAPT | |
| SCHEMBL14342106 | 0.92 | AHR (0.49) | AHRTNKSMEN1KMT2AMAPT | |
| SCHEMBL22312909 | 0.91 | AHR (0.42) | AHRTNKSMEN1KMT2AMAPT | |
| SCHEMBL17987954 | 0.91 | NPC1 (0.45) | AHRTNKSMEN1KMT2AMAPT | |
| SCHEMBL23108697 | 0.90 | AHR (0.53) | AHRTNKSMEN1KMT2AMAPT | |
| SCHEMBL17853268 | 0.88 | PLA2G2A (0.49) | AHRTNKSMEN1KMT2AMAPT | |
| SCHEMBL22312905 | 0.87 | TNKS (0.40) | AHRTNKSMEN1KMT2AMAPT | |
| SCHEMBL26568520 | 0.86 | TNKS (0.37) | AHRTNKSMEN1KMT2AMAPT | |
| SCHEMBL20733886 | 0.84 | PLA2G2A (0.46) | AHRTNKSMEN1KMT2AMAPT | |
| SCHEMBL21128843 | 0.84 | AHR (0.47) | AHRTNKSMEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170213970-A1 | Novel compound and organic electronic device comprising the same | SHANGHAI NICHEM FINE CHEMICAL CO., LTD. (CN) | 2017-07-27 | — | — | US | disclosed |
| US-20170213971-A1 | Novel compound and organic electronic device comprising the same | SHANGHAI NICHEM FINE CHEMICAL CO., LTD. (CN) | 2017-07-27 | — | — | US | disclosed |
| US-20170213971-A1 | Novel compound and organic electronic device comprising the same | SHANGHAI NICHEM FINE CHEMICAL CO., LTD. (CN) | 2017-07-27 | — | — | US | disclosed |
| US-20170213972-A1 | Novel compound and organic electronic device comprising the same | SHANGHAI NICHEM FINE CHEMICAL CO., LTD. (CN) | 2017-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170213972-A1 | Novel compound and organic electronic device comprising the same | CHRM1, CHRM2, ESR1 | AHR 789/4885TNKS 3620/4885MEN1 346/4885 |
| US-20170213970-A1 | Novel compound and organic electronic device comprising the same | CHRM1, CHRM2, ESR1 | AHR 919/4885TNKS 3771/4885MEN1 251/4885 |
| US-20170213971-A1 | Novel compound and organic electronic device comprising the same | CHRM1, CHRM2, ESR1 | AHR 919/4885TNKS 3771/4885MEN1 251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.